Syncope in Elderly People: A Threatening Presentation of Pulmonary Embolism: A Case Report [PDF]
age. Its prognosis is largely unpredictable, pending the origin of the sudden loss of consciousness. We report a case of an old woman affected by severe chronic heart failure, who died soon after the development of an episode of syncope, which was ...
Bilora, Franca +3 more
core
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
Alessandra F. Perna +5 more
doaj +1 more source
The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism [PDF]
Muir, K.W.
core +1 more source
Update on the clinical use of the low-molecular-weight heparin, parnaparin
Giuseppe Camporese1, Enrico Bernardi2, Franco Noventa31Unit of Angiology and 3Department of Clinical and Experimental Medicine, Clinical Epidemiology Group, University Hospital of Padua, Italy; 2Department of Emergency and Accident Medicine, Hospital of ...
Giuseppe Camporese +2 more
doaj
Association between skeletal muscle mass and serum concentrations of lipoprotein lipase, GPIHBP1, and hepatic triglyceride lipase in young Japanese men [PDF]
学位記番号 ...
Matsumoto, Ryutaro +2 more
core
What's the best way to manage upper extremity venous thrombosis? [PDF]
Standard management is best: Start with unfractionated heparin or low-molecular-weight heparin and follow with long-term therapy with a vitamin K antagonist (strength of recommendation [SOR]: C, expert consensus and case reports).
Goodemote, Patricia +2 more
core
Background Sepsis is a life-threatening condition that affects 49 million people annually. Managing sepsis-associated coagulopathy poses a significant challenge due to its high mortality rates in intensive care.
Takaaki Totoki +6 more
doaj +1 more source
To consider the methods for assessing quality and safety of drugs on the basis of low molecular weight heparin.
E. A. Arianova +2 more
doaj
Low-Molecular-Weight Heparin for Adult ICU Patients Who Require Thromboprophylaxis: Protocol for the INCEPT-Thromboprophylaxis Platform Trial Domain. [PDF]
Eck R +10 more
europepmc +1 more source
Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. [PDF]
van Haaps TF +11 more
europepmc +1 more source

